We are excited to announce that the repository will soon undergo an upgrade, featuring a new look and feel along with several enhanced features to improve your experience. Please be on the lookout for further updates and announcements regarding the launch date. We appreciate your support and look forward to unveiling the improved platform soon.
dc.contributor.author | Stander, Andre![]() |
|
dc.contributor.author | Joubert, Fourie![]() |
|
dc.contributor.author | Joubert, Annie M.![]() |
|
dc.date.accessioned | 2011-10-13T10:06:16Z | |
dc.date.available | 2011-10-13T10:06:16Z | |
dc.date.issued | 2011-03 | |
dc.description.abstract | In the present study, Autodock 4.0 was employed to discover potential carbonic anhydrase IX inhibitors that are able to interfere with microtubule dynamics by binding to the Colchicine binding site of tubulin. Modifications at position 2’ of estrone were made to include moieties that are known to improve the antimitotic activity of estradiol analogs. 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-3-ol-17-one estronem (C9) and 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene (C12) were synthesized and tested in vitro. Growth studies were conducted utilizing spectrophotometrical analysis with crystal violet as DNA stain. Compounds C9 and C12 were cytotoxic in MCF-7 and MDA-MB-231 tumorigenic and metastatic breast cancer cells, SNO non-keratinizing squamous epithelium cancer cells and HeLa cells after 48 h exposure. Compounds C9 inhibited cell proliferation to 50% of the vehicle-treated controls from 110-160 nM and C12 at concentrations ranging from 180-220 nM. Confocal microscopy revealed abnormal spindle morphology in mitotic cells. Cell cycle analysis showed an increase in the number of cells in the G2/M fraction after 24 h and an increase in the number of cell in the sub-G1 fraction after 48 h, indicating that the compounds are antimitotic and able to induce apoptosis. | en_US |
dc.description.sponsorship | Medical Research Council of South Africa (AG374, AK076), the Cancer Association of South Africa (AK246), the Struwig-Germeshuysen Cancer Research Trust of South Africa (AJ038) and RESCOM University of Pretoria (A0R984). | en_US |
dc.description.uri | http://www3.interscience.wiley.com/journal/120118371/grouphome/home.html | en_US |
dc.identifier.citation | Stander, A, Joubert, F & Joubert, A 2011, 'Docking, synthesis, and in vitro evaluation of antimitotic estrone analogs', Chemical Biology & Drug Design, vol .77, no. 3, pp. 173-181. | en_US |
dc.identifier.issn | 1747-0277 (print) | |
dc.identifier.issn | 1747-0285 (online) | |
dc.identifier.other | 10.1111/j.1747-0285.2010.01064.x | |
dc.identifier.uri | http://hdl.handle.net/2263/17441 | |
dc.language.iso | en | en_US |
dc.publisher | Wiley-Blackwell | en_US |
dc.rights | Wiley-Blackwell. The definite version is available at www.blackwell-synergy.com. This article is embargoed by the publisher until March 2012. | en_US |
dc.subject | Biological screening | en_US |
dc.subject | Mechanism-based drug design | en_US |
dc.subject | Virtual screening | en_US |
dc.subject.lcsh | Cancer -- Treatment -- Research | en |
dc.title | Docking, synthesis, and in vitro evaluation of antimitotic estrone analogs | en_US |
dc.type | Postprint Article | en_US |